Patients with PSC require regular blood tests, typically every 3-6 months, to monitor liver health, disease progression, and complications.

Doctors primarily use Liver Function Tests (LFTs) to track enzyme levels and overall organ function.

• Alkaline Phosphatase (ALP): The most common marker for PSC; elevated levels usually indicate bile duct damage or obstruction.
• Gamma-Glutamyl Transferase (GGT): Often used alongside ALP to confirm that elevations are liver-related rather than bone-related.
• ALT and AST: These enzymes measure active inflammation and damage to liver cells (hepatocytes).
• Bilirubin: High levels indicate the liver is not properly clearing waste, which can lead to jaundice as the disease progresses.
• Albumin: A protein made by the liver; low levels can signal declining liver function or active inflammatory bowel disease (IBD).

Guidelines generally advise non-invasive abdominal imaging every 6 to 12 months.

• MRI with MRCP: This is the preferred gold standard for routine surveillance. It provides high-quality visualization of the biliary tree and liver parenchyma without radiation.
• Abdominal Ultrasound: Often used annually for gallbladder cancer screening or as an alternative for CCA if MRI is unavailable.
• CT Scan: Generally reserved as an adjunct or alternative when MRI is contraindicated.

Colonoscopy is essential for diagnosing concomitant Inflammatory Bowel Disease (IBD) and screening for Colorectal Cancer (CRC), which occurs at higher rates in PSC patients.

Initial Diagnosis: A colonoscopy with random biopsies is mandatory for all newly diagnosed PSC patients to evaluate for subclinical IBD.

Surveillance Frequency:

• PSC with IBD: Annual surveillance (every 1–2 years) is required, often with dysplasia surveillance.
• PSC without IBD: Screening is typically recommended every 3–5 years, or sooner if IBD symptoms develop.
• Procedural Quality: High-quality bowel preparation is critical; suboptimal prep is reported in approximately one-third of cases and can hinder the detection of flat dysplastic lesions.

While no curative diet exists, updated 2026 federal guidelines emphasize nutrient density to support chronic disease management.

• Protein & Fats: Prioritize high-quality protein (1.2–1.6 g/kg) and healthy fats from whole sources like seafood, nuts, and avocados.
• Deficiency Risks: PSC patients are at high risk for fat-soluble vitamin (A, D, E, K) deficiencies due to impaired bile flow.
• Avoidances: Strictly limit highly processed foods, refined carbohydrates, and added sugars, which may exacerbate inflammation or gut microbiota dysbiosis.
• Hydration: Maintain consistent water intake; limit or avoid alcohol to reduce additional liver stress.

Tracking symptoms helps identify disease progression and clinical trial eligibility.

• Core Symptoms: Patients should monitor the frequency and severity of pruritus (itching), fatigue, and abdominal pain.
• Patterns: Pruritus often worsens in the evening and during winter months.
• Progression Markers: Be alert for “red flag” symptoms such as unexplained weight loss, fever, or night sweats, which may indicate advanced disease or complications.

Living with a chronic, rare disease like PSC carries a significant psychological burden, including procedure-related anxiety and depression.

• Support Organizations: Organizations such as PSC Partners Seeking a Cure host community summits, peer-led support, and specialized webinars for patients and caregivers.